Active Substance: Pioglitazone, Glimepiride.
Overview
Welcome to Dwaey, specifically on DUETACT 30/2mg page.
This medicine contains an important and useful components, as it consists of
Pioglitazone, Glimepirideis available in the market in concentration
Glimepiride + Pioglitazone
Pioglitazone, like other thiazolidinediones, can cause dose-related fluid retention when used alone or in combination with other antidiabetic medications and is most common when is used in combination with insulin. Fluid retention may lead to or exacerbate congestive heart failure. Patients should be observed for signs and symptoms of congestive heart failure. If congestive heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of must be considered. Lactation: Not known if crosses into breast milk, discontinue drug or breastfeeding
Type 2 DM
History of allergic reaction to sulfonamide derivative. Patient w/ established CHF (NYHA class III or IV). Not intended for treatment of type 1 DM or diabetic ketoacidosis.
>10% Peripheral edema (6-12%),Upper respiratory tract infection (12-15%),Weight gain (9-13%),Hypoglycemia (13-16%) 1-10% Anemia (<2%),Limb pain (4-5%),Urinary tract infection (6-7%),Headache (4-7%),Diarrhea (4-6%),Nausea (4-5%)
3
Pioglitazone, a thiazolidinedione, reduces blood glucose by improving target cell response to insulin w/o increasing pancreatic insulin secretion and is dependent on the presence of insulin for activity. Glimepiride, a sulfonylurea, stimulates insulin release from the pancreatic beta-cells. It also reduces glucose output from the liver and increases insulin sensitivity at peripheral target sites.
Increased plasma levels w/ CYP2C8 inhibitors (e.g. gemfibrozil) and CYP2C9 inhibitors (e.g. fluconazole). Decreased plasma levels w/ CYP2C8 inducers (e.g. rifampicin). Colesevelam may reduce the max plasma concentration and total exposure of glimepiride. Concominant use w/ oral miconazole may lead to severe hypoglycaemia.
Information not available